Direct-to-consumer advertising distorts prescription drugs’ benefits and costs
Common Sense Family Doctor
FEBRUARY 15, 2025
On Sensible Medicine, Dr. Edward Livingston pointed out that the manufacturer, AbbVie, spent $580 million on DTCA for this drug in 2023, or $290 for each of the 2 million potential patients in the United States. The annual price of risankizumab is $288,000, so this is still a huge bargain for the company given the potential returns.
40 
Let's personalize your content